Multivariate Analyses of Socio-economic Inequities in Parental Awareness and Utilization of Meningococcal Serogroup B Vaccines

Liping Huang, MD, MA, MS¹ Amanda Dempsey, MD² Alex Galitsky³, Mansour Fahimi, PhD⁴ Amit Srivastava, PhD¹ ¹Pfizer Inc, Collegeville, PA; ²University of Colorado, Denver, CO; ³GfK, New York, NY; ⁴GfK, North Potomac, MD


OBJECTIVE

To examine factors associated with awareness and utilization of MenB vaccines for parents and caregivers of adolescents aged 16-19 years in the United States

BACKGROUND

- Serogroup B was the leading cause of meningococcal disease among US 16-23 year-olds, representing 60% of cases in
- While two MenACWY and two MenB vaccines have been licensed by the FDA, only MenACWY vaccines are recommended by the ACIP for all 11 year olds (Category A), with a booster at 16 years. In contrast, Men B vaccines are recommended for 16-23 years olds based on individual clinical decision making (Category B).
- Recent published studies indicated that:
- HCP recommendation is critical for parent and caregiver vaccine awareness
- C.S. Mott Children's Hospital, University of Michigan conducted a national survey in January 2017, showing that more than 1 out of 3 parents did not know when or if their teen was due for another vaccine and named the HCP's office as the primary information source for knowing when teen vaccines are due.3


Figure 1: Parents expect HCPs to guide them on teen vaccines



HCPs have a poor understanding of ACIP Category B recommendations

In a nationally representative sample of pediatricians surveyed between October and December of 2016, 64% reported understanding the difference between a Category A and Category B ACIP recommendations; however, 73% of these pediatricians incorrectly defined a Category B recommendation.

Figure 2: Category B recommendation is poorly understood by pediatricians



METHODS



 An online quantitative survey was fielded among a nationally representative sample of US parents of adolescents aged 16-19 years recruited from GfK's KnowledgePanel®(KP).

- **Inclusion criteria:**
- Agreement to confidentiality statement
- English or Spanish speaking respondent aged over 18 years
- Respondents are parents or guardians of at least one dependent aged 16-19 years




 A structured quantitative, 25-minute selfadministered online questionnaire with a short screening survey to determine eligibility was conducted.

- For self-reported vaccinated respondents, MenB vaccination verification through EMRs or HCPs was performed.
- Sample weights were adjusted to known population distributions obtained from the Current Population Survey (CPS) age 35+ along pre-specified dimensions: gender, race/ethnicity, geographic region, education attainment, household income and language proficiency.
- Univariate analysis was conducted to describe factors in relation to MenB vaccine awareness and use (logistic procedure in SAS version
- Logistic regression models and Classification And Regression Trees (CART) were conducted to examine most influential factors associated with MenB vaccine awareness and utilization; special procedures were used to incorporate survey weights.



Figure 3: Information collected from survey



What is KnowledgePanel®?

KP is GfK's online panel representative of the US population for which probabilitybased methods are used for recruitment. This panel is routinely used for government and academic research purposes to support publications in peer-reviewed journals. Samples from KP cover all households, including those without Internet access, as members from such households are furnished with a free tablet and Internet


Social, economic and demographic factors potentially associated with awareness, access to care, decision making, and vaccine use were collected.


RESULTS Figure 4: Flow chart of study population Of the 23,892 screened for Total Screened Number of respondents participation in the survey, 619 weighted number of US population qualified to participate. Of the weighted sample, 57% were Parents/Guardians of 16-19 year olds unaware of MenB vaccines (Figure 1). 619 / 26.266.700* 57% of respondents MenB vaccination **Unaware of MenB Vaccines Aware of MenB Vaccines** status was verified through EMRs or 155 / 14.850.080 (57%) 464 / 11,416,620 (43%) HCPs. Do Not Intend to Vaccinate Vaccinated **Intend to Vaccinate Interest to Vaccinate** No Interest to Vaccinate 158 / 4,096,409 (36%) 155 / 5,155,347 (45%) 151 / 2,164,864 (19%) 52 / 5,346,029 (36%) 103 / 9,504,051 (64%) **Vaccinated / Intend to Vaccinate** Vaccinated vs. Intend to **Unaware but Interested** Aware vs Not aware vs. Do Not Intend to Vaccinate Vaccinate but not yet vaccinated vs. Unaware Not Interested Were unaware Were aware Were aware Of unaware 57% 36% of MenB but do not and intend to parents were **Highlighted Results** interested in vaccines intend to vaccinate but Didn't receive vaccinate and looking for not vaccinated Males Didn't receive From Logistic recommendation recommendation Hispanic or non-white information of from HCP from HCP Aware of MenACWY **Regression Models** MenB vaccines Lower educational vaccine Don't have HCPs don't know attainment (Table 1) employer-based children well HCPs don't know medical insurance children well or no insurance


Table 1: Factors associated with MenB vaccine awareness or utilization from Logistic Regression Models

Category	Odds Ratios and Associated 95% Confidence Intervals from Survey* statistical significance (p-value < 0.05)			
	Aware of MenB Vaccines v. Unaware	Vaccinated/Intend to Vaccinate v. Not Intend to Vaccinate	Vaccinated v. Intend to Vaccinate	Unaware and Interested v. Not Interested
Age	1.00 (0.97, 1.04)	1.01 (0.98, 1.04)	1.00 (0.96, 1.03)	1.02 (0.95, 1.09)
Gender: Male v. Female	0.43 (0.26, 0.70)*	1.09 (0.64, 1.84)	0.60 (0.30, 1.21)	0.40 (0.13, 1.24)
Hispanic v. Black and Others, Non-Hispanic	1.01 (0.47, 2.18)	0.66 (0.26, 1.71)	1.11 (0.39, 3.14)	5.05 (1.13, 22.63)*
White, Non-Hispanic v. Black and Others, Non-Hispanic	2.20 (1.09, 4.46)*	0.54 (0.25, 1.15)	1.17 (0.51, 2.71)	1.39 (0.29, 6.69)
Education: High School or below v. Some college or above	0.61 (0.34,1.09)	0.97 (0.54, 1.72)	1.13 (0.55, 2.29)	1.07 (0.33, 3.48)
Property: Rent v. Own	1.25 (0.67, 2.31)	1.18 (0.60, 2.33)	1.67 (0.67, 4.18)	1.79 (0.49, 6.49)
Annual Household Income	0.91 (0.69, 1.20)	0.93 (0.71, 1.21)	0.82 (0.55, 1.23)	1.70 (0.99, 2.92)
nsurance: Employed-Based v. No Insurance	0.71 (0.29, 1.72)	1.10 (0.38, 3.14)	3.34 (1.09, 10.21)*	0.89 (0.19, 4.26)
nsurance: Medicaid v. No Insurance	0.47 (0.16, 1.35)	0.32 (0.09, 1.12)	1.56 (0.34, 7.15)	1.28 (0.16, 10.32)
nsurance: Others v. No Insurance	0.44 (0.16, 1.18)	0.99 (0.31, 3.13)	3.66 (1.06, 12.66)*	1.67 (0.29, 9.66)
Awareness of MenB Outbreaks: No v. Yes	0.96 (0.59, 1.55)	0.88 (0.42, 1.84)	1.10 (0.51, 2.37)	0.58 (0.11, 3.13)
Awareness of MenACWY Vaccine: Yes v. No	0.52 (0.23, 1.19)	1.36 (0.80, 2.32)	1.02 (0.55, 1.90)	3.02 (1.03, 8.81)*
Generally see the same HCP: No v. Yes	0.76 (0.40, 1.45)	0.76 (0.32, 1.81)	3.34 (1.29, 8.62)*	1.79 (0.57, 5.68)
hink HCP knows you or your child well: No v. Yes	0.53 (0.30, 0.96)*	0.43 (0.20, 0.93)*	0.85 (0.32, 2.29)	0.28 (0.07, 1.05)
HCP ever recommended MenB Vaccine: Yes v. No	N/A	4.81 (2.46, 9.35)*	5.66 (2.49, 12.87)*	N/A
First became aware of MenB vaccine via HCP: Yes v. No	N/A	1.29 (0.70, 2.39)	0.64 (0.30, 1.33)	N/A

Figure 5: Most influential variables generated from classification/regression trees (CART) to predict awareness and MenB vaccine utilization







- Race/ethnicity and household income were key factors in predicting awareness of MenB vaccine (CART 1) and lack of awareness, but interested (CART 4).
- HCP recommendation was the most influential factor to predict the MenB vaccination status (CART 2 & 3).
- Results from CART are consistent with results observed from logistic regression models.

CONCLUSIONS

- Provider discussion and recommendation remain the most significant catalyst for MenB vaccine awareness and receipt, similar to other adolescent vaccines like HPV and MenACWY.
- There is evidence of racial and socioeconomic disparities in MenB awareness among the vaccine-eligible adolescent population in the United States.
- In the context of recently published studies that demonstrate substantial gaps in provider understanding, our data underscores the critical need for efforts to (1) improve knowledge and awareness of MenB vaccines (2) improve provider understanding of the ACIP Category B recommendation and (3) develop tools to aid consistent implementation of ACIP Category B recommendation for MenB vaccines, including cues for providers to initiate discussions with adolescent patients and utilizing CDC's immunization platforms.

REFERENCES AND DISCLOSURE

- . CDC Enhanced Meningococcal Disease Surveillance Reports, 2016. 5. Srivastava A, et al. 2018 PAS Meeting, Board #641.
- Patton ME, et al. MMWR 2017;66:509-513

. Kempe M, et al. 2017 PAS Meeting, Abstract #3340.6.

Children's Health. 2017; 29(4).

https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-

- . C.S. Mott Children's Hospital, University of Michigan National Poll on
- 6. Kempe A et al. Adoption of Serogroup B Meningococcal Vaccine Recommendations. Pediatrics. 2018;142(3):e20180344 7. Kempe A et al (2018) Knowledge and Attitudes Regarding Category B
 - ACIP Rec. among Primary Care Providers for Children, Acad. Pediatrics, https://doi.org/10.1016/j.acap.2018.04.005 Funding for this research provided by Pfizer Inc.